1085 related articles for article (PubMed ID: 16606670)
1. Tissue expression of PD-L1 mediates peripheral T cell tolerance.
Keir ME; Liang SC; Guleria I; Latchman YE; Qipo A; Albacker LA; Koulmanda M; Freeman GJ; Sayegh MH; Sharpe AH
J Exp Med; 2006 Apr; 203(4):883-95. PubMed ID: 16606670
[TBL] [Abstract][Full Text] [Related]
2. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
[TBL] [Abstract][Full Text] [Related]
3. Protective role of programmed death 1 ligand 1 (PD-L1)in nonobese diabetic mice: the paradox in transgenic models.
Wang CJ; Chou FC; Chu CH; Wu JC; Lin SH; Chang DM; Sytwu HK
Diabetes; 2008 Jul; 57(7):1861-9. PubMed ID: 18420489
[TBL] [Abstract][Full Text] [Related]
4. Programmed death 1 ligand (PD-L) 1 and PD-L2 limit autoimmune kidney disease: distinct roles.
Menke J; Lucas JA; Zeller GC; Keir ME; Huang XR; Tsuboi N; Mayadas TN; Lan HY; Sharpe AH; Kelley VR
J Immunol; 2007 Dec; 179(11):7466-77. PubMed ID: 18025191
[TBL] [Abstract][Full Text] [Related]
5. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
[TBL] [Abstract][Full Text] [Related]
6. The function of donor versus recipient programmed death-ligand 1 in corneal allograft survival.
Shen L; Jin Y; Freeman GJ; Sharpe AH; Dana MR
J Immunol; 2007 Sep; 179(6):3672-9. PubMed ID: 17785803
[TBL] [Abstract][Full Text] [Related]
7. Blockade of programmed death-1 ligands on dendritic cells enhances T cell activation and cytokine production.
Brown JA; Dorfman DM; Ma FR; Sullivan EL; Munoz O; Wood CR; Greenfield EA; Freeman GJ
J Immunol; 2003 Feb; 170(3):1257-66. PubMed ID: 12538684
[TBL] [Abstract][Full Text] [Related]
8. Endothelial programmed death-1 ligand 1 (PD-L1) regulates CD8+ T-cell mediated injury in the heart.
Grabie N; Gotsman I; DaCosta R; Pang H; Stavrakis G; Butte MJ; Keir ME; Freeman GJ; Sharpe AH; Lichtman AH
Circulation; 2007 Oct; 116(18):2062-71. PubMed ID: 17938288
[TBL] [Abstract][Full Text] [Related]
9. Expression of programmed death 1 ligands by murine T cells and APC.
Yamazaki T; Akiba H; Iwai H; Matsuda H; Aoki M; Tanno Y; Shin T; Tsuchiya H; Pardoll DM; Okumura K; Azuma M; Yagita H
J Immunol; 2002 Nov; 169(10):5538-45. PubMed ID: 12421930
[TBL] [Abstract][Full Text] [Related]
10. LAG-3, TGF-β, and cell-intrinsic PD-1 inhibitory pathways contribute to CD8 but not CD4 T-cell tolerance induced by allogeneic BMT with anti-CD40L.
Lucas CL; Workman CJ; Beyaz S; LoCascio S; Zhao G; Vignali DA; Sykes M
Blood; 2011 May; 117(20):5532-40. PubMed ID: 21422469
[TBL] [Abstract][Full Text] [Related]
11. Blockade of B7-H1 on macrophages suppresses CD4+ T cell proliferation by augmenting IFN-gamma-induced nitric oxide production.
Yamazaki T; Akiba H; Koyanagi A; Azuma M; Yagita H; Okumura K
J Immunol; 2005 Aug; 175(3):1586-92. PubMed ID: 16034097
[TBL] [Abstract][Full Text] [Related]
12. Programmed death ligand 1 regulates a critical checkpoint for autoimmune myocarditis and pneumonitis in MRL mice.
Lucas JA; Menke J; Rabacal WA; Schoen FJ; Sharpe AH; Kelley VR
J Immunol; 2008 Aug; 181(4):2513-21. PubMed ID: 18684942
[TBL] [Abstract][Full Text] [Related]
13. Impairment of the programmed cell death-1 pathway increases atherosclerotic lesion development and inflammation.
Bu DX; Tarrio M; Maganto-Garcia E; Stavrakis G; Tajima G; Lederer J; Jarolim P; Freeman GJ; Sharpe AH; Lichtman AH
Arterioscler Thromb Vasc Biol; 2011 May; 31(5):1100-7. PubMed ID: 21393583
[TBL] [Abstract][Full Text] [Related]
14. PD-L1 and PD-L2 modulate airway inflammation and iNKT-cell-dependent airway hyperreactivity in opposing directions.
Akbari O; Stock P; Singh AK; Lombardi V; Lee WL; Freeman GJ; Sharpe AH; Umetsu DT; Dekruyff RH
Mucosal Immunol; 2010 Jan; 3(1):81-91. PubMed ID: 19741598
[TBL] [Abstract][Full Text] [Related]
15. Peripheral deletional tolerance of alloreactive CD8 but not CD4 T cells is dependent on the PD-1/PD-L1 pathway.
Haspot F; Fehr T; Gibbons C; Zhao G; Hogan T; Honjo T; Freeman GJ; Sykes M
Blood; 2008 Sep; 112(5):2149-55. PubMed ID: 18577709
[TBL] [Abstract][Full Text] [Related]
16. Forced expression of programmed death-1 gene on T cell decreased the incidence of type 1 diabetes.
Won TJ; Jung YJ; Kwon SJ; Lee YJ; Lee DI; Min H; Park ES; Joo SS; Hwang KW
Arch Pharm Res; 2010 Nov; 33(11):1825-33. PubMed ID: 21116786
[TBL] [Abstract][Full Text] [Related]
17. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2.
Carter L; Fouser LA; Jussif J; Fitz L; Deng B; Wood CR; Collins M; Honjo T; Freeman GJ; Carreno BM
Eur J Immunol; 2002 Mar; 32(3):634-43. PubMed ID: 11857337
[TBL] [Abstract][Full Text] [Related]
18. Deficiency in B7-H1 (PD-L1)/PD-1 coinhibition triggers pancreatic beta-cell destruction by insulin-specific, murine CD8 T-cells.
Rajasalu T; Brosi H; Schuster C; Spyrantis A; Boehm BO; Chen L; Reimann J; Schirmbeck R
Diabetes; 2010 Aug; 59(8):1966-73. PubMed ID: 20484136
[TBL] [Abstract][Full Text] [Related]
19. Targeting the CXCR4-CXCL12 axis mobilizes autologous hematopoietic stem cells and prolongs islet allograft survival via programmed death ligand 1.
Fiorina P; Jurewicz M; Vergani A; Petrelli A; Carvello M; D'Addio F; Godwin JG; Law K; Wu E; Tian Z; Thoma G; Kovarik J; La Rosa S; Capella C; Rodig S; Zerwes HG; Sayegh MH; Abdi R
J Immunol; 2011 Jan; 186(1):121-31. PubMed ID: 21131428
[TBL] [Abstract][Full Text] [Related]
20. Striking dichotomy of PD-L1 and PD-L2 pathways in regulating alloreactive CD4(+) and CD8(+) T cells in vivo.
Habicht A; Kewalaramani R; Vu MD; Demirci G; Blazar BR; Sayegh MH; Li XC
Am J Transplant; 2007 Dec; 7(12):2683-92. PubMed ID: 17924994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
